Now Is The Time For You To Know The Truth About 50501-07-0

There is still a lot of research devoted to this compound(SMILES:O=C(C1NC2=C(C=CC=C2)C1)OCC)Formula: C11H13NO2, and with the development of science, more effects of this compound(50501-07-0) can be discovered.

Kim, Dong H.; Guinosso, Charles J.; Buzby, George C. Jr.; Herbst, David R.; McCaully, Ronald J.; Wicks, Thomas C.; Wendt, Robert L. published an article about the compound: Ethyl indoline-2-carboxylate( cas:50501-07-0,SMILESS:O=C(C1NC2=C(C=CC=C2)C1)OCC ).Formula: C11H13NO2. Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:50501-07-0) through the article.

Stereoisomers of 1-(3-mercapto-2-methyl-1-oxopropyl)indoline-2-carboxylic acid (I) and related compounds were synthesized and their ability to inhibit angiotensin converting enzyme (ACE) [9015-82-1] and to lower the systolic blood pressure of spontaneously hypertensive rats (SHR) examined All 4 possible stereoisomers of the precursor 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]indoline-2-carboxylic acid were characterized with absolute stereochem. assignment. The removal of the benzoyl group of the precursor showed in vitro ACE inhibitory activity; the stereoisomer having the R,R configuration was essentially inactive. The mercaptan (S,S)-I was the most active ACE inhibitor, showing in vitro potency 3 times that of captopril. (S,S)-I exhibited oral antihypertensive activity 27 times that of captopril. The thio lactone obtained by cyclization of (S,S)-I as a potential prodrug was less potent than the parent compound in the ACE inhibitory and antihypertensive tests. Structure-activity relations are discussed.

There is still a lot of research devoted to this compound(SMILES:O=C(C1NC2=C(C=CC=C2)C1)OCC)Formula: C11H13NO2, and with the development of science, more effects of this compound(50501-07-0) can be discovered.

Reference:
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics